

Under the Paperwork Reduction Project  
Subpart 1.00  
OCT 19 2007  
PATENT & TRADEMARK OFFICE

(use as many sheets as necessary)

Application Number	09/699,003
Filing Date	October 26, 2000
First Named Inventor	M. Rigdon Lentz
Group Art Unit	3772
Examiner Name	P. Bianco
Attorney Docket Number	LEN 101 CIP CON

Sheet	1	of	4	Attorney Docket Number	LEN 101 CIP CON
-------	---	----	---	------------------------	-----------------

[illegible][illegible]

Examiner's Signature	/Leslie Deak/	Date Considered	8 June 2009
----------------------	---------------	-----------------	-------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

ALL references considered except where lined through. /LD/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/699,003
		Filing Date	October 26, 2000
		First Named Inventor	M. Rigdon Lentz
		Group Art Unit	3772
		Examiner Name	P. Bianco
		Attorney Docket Number	LEN 101 CIP CON
Sheet	2	of	4

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		AGISHI, Anion-blood contact (ABC reaction) in patients treated by LDL apheresis with dextran sulfate-cellulose column while receiving ACE inhibitors (letter). JAMA; 271:195-6(1994).	
		BANYAI et al., "Therapeutic efficiency of lipoprotein(a) reduction by low-density lipoprotein immunoapheresis," <i>Metabolism</i> 47(9):1058-1064 (1998).	
		CYTOLOGIC, "Unleash Immunotherapy," CytoLogic non CDA info.doc , pp.1-10 (April 27, 2006).	
		DAUGHERTY, et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," <i>Nucl. Acids Res.</i> 19: 2471-2476 (1991).	
		GUYTON and HALL, <i>Textbook of Medical Physiology</i> 9 <sup>th</sup> ed. Pp. 299	
		HARLOW et al., <i>Antibodies, A Laboratory Manual</i> , Chapter 13, "Immunoaffinity Purification," pp. 511-552, 1988	
		Hemostasis and Thrombosis: Basic Principles and Clinical Practice 2nd Ed., Colman, R.W., et al., p. 263 (J.B.Lippincott, Philadelphia, PA 1987).	
		HONG et al., "Interleukin adhesion molecule-1 expression induced by interleukin (IL)-1 beta or an IL-1 beta fragment is blocked by an IL-1 receptor antagonist and a soluble IL-1 receptor," <i>Journal of Neuroimmunology</i> , 44(2):163-170 (1993).	
		IBM Technical Disclosure Bulletin, Vol 19, No 3. August 1976 pp. 765-768	
		JABLONSKA & PEITRUSKA, "Release of soluble tumor necrosis factor receptors from polymorphonuclear cells of breast cancer patients," <i>Arch Immunol Ther Exp (Warsz)</i> . 45(5-6):449-53 (1997).	
		JANEWAY, et al. <i>Immunobiology: The Immune System in Health and Disease</i> , 4 <sup>th</sup> Ed. Pp.102	

Examiner's Signature	/Leslie Deak/	Date Considered	8 June 2009
----------------------	---------------	-----------------	-------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

All references considered except where lined through. /LD/



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		<b>Application Number</b>  <b>Filing Date</b> <b>First Named Inventor</b> <b>Group Art Unit</b> <b>Examiner Name</b> <b>Attorney Docket Number</b>	09/699,003  October 26, 2000 M. Rigdon Lentz 3772 P. Bianco LEN 101 CIP CON
Sheet	3	of	4

OTHER ART – NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>1</sup>
		KAMINSKA, et al. "Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I—an independent prognostic factor," <i>Tumour Biol.</i> 26(4):186-94(2005).	
		KAMINSKA, et al. "Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF - an independent prognostic factor," <i>Oncology</i> 70(2):115-25(2006).	
		KOJIMA, et al. "Effect of nafamostat mesilate on bradykinin generation during lowdensity lipoprotein apheresis using a dextran sulfate cellulose column," <i>ASAIO Trans</i> 37: 644-8(1991).	
		MARUYAMA, et al. "Evidence for aberrant activation of the interleukin-2 autocrine loop by HTLV-1-encoded p40x and T3/Ti complex triggering," <i>Cell</i> . 48(2):343-350(1987).	
		MITTEREGGER, et al., "In vitro cell culture systems as the basis for an extracorporeal blood purification strategy in multiorgan failure treatment", <i>Ther Apher.</i> , 3(3):257-63 (1999).	
		NATIONAL CANCER INSTITUTE, "Biological Therapies for Cancer: Questions and Answers," National Cancer Institute FactSheet (08-16-2004).	
		OLD, "Antitumor activity of microbial products and tumor necrosis factor, and Bonavida B, et al., (eds): Tumor Necrosis Factor/Cachecin and Related Cytokines, Basel, Karger, p7 (1988).	
		PALASZYSKI, "Synthetic C-terminal peptide of IL-1 functions as a binding domain as well as an antagonist for the IL-1 receptor," <i>Biochemical and Biophysical Research Communications</i> , 147(1):204-211(1987).	
		PENNICA et al., "Characterization of a recombinant extracellular domain of the type 1 tumor necrosis factor receptor: evidence for tumor necrosis factor-alpha induced receptor aggregation," <i>Biochemistry</i> 31(4):1134-1141(1992).	
		PENNICA et al., "Biochemical characterization of the extracellular domain of the 75-kilodalton tumor necrosis factor receptor," <i>Biochemistry</i> 32(12): 3131-3138(1993).	
		Product description: catalog number AB-225-PB catalog of R&D Systems. (1994).	

Examiner's Signature	/Leslie Deak/	Date Considered	8 June 2009
----------------------	---------------	-----------------	-------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

All references considered except where lined through. /LD/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Application Number</b>	09/699,003
		<b>Filing Date</b>	October 26, 2000
		<b>First Named Inventor</b>	M. Rigdon Lentz
		<b>Group Art Unit</b>	3772
		<b>Examiner Name</b>	P. Bianco
		<b>Attorney Docket Number</b>	LEN 101 CIP CON
<b>Sheet</b>	4	<b>of</b>	4

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>1</sup>
		Product description: catalog number AB-226-PB catalog of R&D Systems (1994).	
		Product description: catalog numbers FAB225F catalog of R&D Systems (1998).	
		Product description: catalog numbers MAB225 catalog of R&D Systems (1998),	
		Product description: catalog numbers AF-425-PB catalog of R&D Systems (1998).	
		Product description: of antibody AHR3912. Biosource catalog	
		SHIBATA, et al., "Changes of cell-mediated immunity with an advance of cancer-relation to the th1/th2 balance and inhibitors of th1 cytokines", <i>Biotherapy</i> , 12(5):715-17 (1998).	
		VERMA et al., "Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems," <i>Journal of Immunological Methods</i> , 216(1-2):165-181(1998).	
		WARZOGA, et al. "Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients," <i>J Clin Oncol.</i> 15(2):499-508(1997).	
		WINTER, et al. "Synthetic human antibodies and a strategy for protein engineering," <i>FEBS Letters</i> , 430:92-94(1998).	
		YAMAZAKI et al. Biocompatibility of plasma separator of an improved cellulose acetate hollow fiber. In: Sieberth HG (ed). Plasma Exchange. New York: fk Schattauer, 45-51(1980).	

<b>Examiner's Signature</b>	/Leslie Deak/	<b>Date Considered</b>	8 June 2009
-----------------------------	---------------	------------------------	-------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commission for Patent, Washington, DC 20231.

All references considered except where lined through. /LD/